- Home
- ZURA vs RDZN Comparison
ZURA vs RDZN Comparison
Compare ZURA & RDZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZURA
- RDZN
- Stock Information
- Founded
- ZURA 2022
- RDZN 2015
- Country
- ZURA United States
- RDZN United States
- Employees
- ZURA N/A
- RDZN N/A
- Industry
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- RDZN Blank Checks
- Sector
- ZURA Health Care
- RDZN Finance
- Exchange
- ZURA Nasdaq
- RDZN Nasdaq
- Market Cap
- ZURA 76.6M
- RDZN 79.4M
- IPO Year
- ZURA N/A
- RDZN N/A
- Fundamental
- Price
- ZURA $1.21
- RDZN $0.78
- Analyst Decision
- ZURA Buy
- RDZN Strong Buy
- Analyst Count
- ZURA 7
- RDZN 2
- Target Price
- ZURA $14.33
- RDZN $5.00
- AVG Volume (30 Days)
- ZURA 330.0K
- RDZN 243.1K
- Earning Date
- ZURA 05-08-2025
- RDZN 07-01-2025
- Dividend Yield
- ZURA N/A
- RDZN N/A
- EPS Growth
- ZURA N/A
- RDZN N/A
- EPS
- ZURA N/A
- RDZN N/A
- Revenue
- ZURA N/A
- RDZN $42,893,256.00
- Revenue This Year
- ZURA N/A
- RDZN $4.52
- Revenue Next Year
- ZURA N/A
- RDZN $53.72
- P/E Ratio
- ZURA N/A
- RDZN N/A
- Revenue Growth
- ZURA N/A
- RDZN 2.79
- 52 Week Low
- ZURA $0.97
- RDZN $0.71
- 52 Week High
- ZURA $6.35
- RDZN $4.43
- Technical
- Relative Strength Index (RSI)
- ZURA 43.46
- RDZN 41.34
- Support Level
- ZURA $1.17
- RDZN $0.68
- Resistance Level
- ZURA $1.55
- RDZN $1.01
- Average True Range (ATR)
- ZURA 0.14
- RDZN 0.11
- MACD
- ZURA -0.02
- RDZN -0.01
- Stochastic Oscillator
- ZURA 7.83
- RDZN 31.94
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.
About RDZN Roadzen Inc.
Roadzen Inc is an insurance technology company on a mission to transform global auto insurance powered by advanced AI. Its clients comprise major insurers, fleets, and carmakers to small fleets, brokers, and insurance agents that use Roadzen's technology to build new products, sell insurance, process claims, and improve road safety. The company's work in telematics and computer vision has earned recognition as an AI innovator by publications such as Forbes, Fortune, and Financial Express.